➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Johnson and Johnson
Medtronic
Express Scripts

Last Updated: February 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENABLEX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Enablex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00127270 Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed Procter and Gamble Phase 4 2005-05-01 This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00127270 Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed Novartis Phase 4 2005-05-01 This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00170755 A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder Completed Novartis Phase 3 2002-04-01 This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.
NCT00170768 Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over Completed Novartis Phase 2 2005-02-01 The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
NCT00171145 A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. Completed Novartis Phase 3 2004-04-01 This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
NCT00171184 Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder Completed Procter and Gamble Phase 4 2005-04-01 The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged >Ý 65 years with OAB.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Enablex

Condition Name

Condition Name for Enablex
Intervention Trials
Overactive Bladder 5
Healthy 2
Overactive Bladder Syndrome 2
Bioequivalency 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Enablex
Intervention Trials
Urinary Bladder, Overactive 9
Urologic Diseases 1
Urinary Bladder Diseases 1
Enuresis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Enablex

Trials by Country

Trials by Country for Enablex
Location Trials
United States 113
Canada 6
Uruguay 2
Chile 1
South Africa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Enablex
Location Trials
New Jersey 7
Florida 5
California 5
Arizona 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Enablex

Clinical Trial Phase

Clinical Trial Phase for Enablex
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Enablex
Clinical Trial Phase Trials
Completed 11
Unknown status 2
Withdrawn 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Enablex

Sponsor Name

Sponsor Name for Enablex
Sponsor Trials
Novartis 8
Procter and Gamble 5
Laboratorio Elea S.A.C.I.F. y A. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Enablex
Sponsor Trials
Industry 19
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
AstraZeneca
Harvard Business School
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.